HOLX has been the topic of a number of other research reports. Needham & Company LLC restated a hold rating on shares of Hologic in a research note on Thursday, July 28th. Leerink Swann restated an outperform rating and set a $46.00 price objective on shares of Hologic in a research note on Monday, October 3rd. Zacks Investment Research lowered Hologic from a buy rating to a hold rating in a research note on Friday, August 5th. Barclays PLC restated an equal weight rating and set a $42.00 price objective on shares of Hologic in a research note on Sunday, July 31st. Finally, Morgan Stanley raised their price objective on Hologic from $38.00 to $40.00 and gave the stock an equal weight rating in a research note on Thursday, July 28th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $42.76.
Hologic (NASDAQ:HOLX) traded up 0.34% during mid-day trading on Friday, hitting $38.45. The stock had a trading volume of 1,547,204 shares. The firm has a market capitalization of $10.67 billion, a price-to-earnings ratio of 42.39 and a beta of 1.00. Hologic has a one year low of $31.84 and a one year high of $41.66. The stock’s 50 day moving average price is $38.49 and its 200 day moving average price is $36.36.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The firm had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. During the same quarter last year, the company earned $0.43 EPS. The company’s revenue was up 3.4% on a year-over-year basis. Analysts forecast that Hologic will post $1.94 EPS for the current year.
In other news, Director Nancy Leaming sold 8,179 shares of the business’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the transaction, the director now directly owns 67,140 shares of the company’s stock, valued at approximately $2,484,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Karleen Marie Oberton sold 31,470 shares of the business’s stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $40.00, for a total value of $1,258,800.00. Following the completion of the transaction, the vice president now directly owns 17,005 shares in the company, valued at $680,200. The disclosure for this sale can be found here. 0.84% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in HOLX. BlackRock Japan Co. Ltd increased its position in shares of Hologic by 3.1% in the first quarter. BlackRock Japan Co. Ltd now owns 313,303 shares of the company’s stock worth $10,809,000 after buying an additional 9,312 shares in the last quarter. NN Investment Partners Holdings N.V. acquired a new position in shares of Hologic during the first quarter worth about $1,270,000. State Street Corp increased its position in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares in the last quarter. UBS Group AG increased its position in shares of Hologic by 5.8% in the first quarter. UBS Group AG now owns 794,751 shares of the company’s stock worth $27,419,000 after buying an additional 43,652 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in shares of Hologic by 1.2% in the first quarter. UBS Asset Management Americas Inc. now owns 637,813 shares of the company’s stock worth $22,006,000 after buying an additional 7,810 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.